#Can­nes­Lions2022: Ad­dress­ing clin­i­cal tri­al di­ver­si­ty prob­lems will take 're­al work now,' pan­elists say

CANNES —  As a young sci­en­tist, Som­mer Bazuro was look­ing at on­col­o­gy da­ta when she re­al­ized that the pa­tient pop­u­la­tion was not at all rep­re­sen­ta­tive of the de­mo­graph­ics most like­ly to suf­fer and die from can­cer.

Think­ing it must be an iso­lat­ed in­ci­dent, she turned to peer-re­viewed pub­li­ca­tions and be­gan talk­ing to on­col­o­gists, on­ly to dis­cov­er that a lack of di­ver­si­ty in clin­i­cal tri­als was par for the course. Black and His­pan­ic pa­tients typ­i­cal­ly don’t even reach lev­els of rep­re­sen­ta­tion con­sis­tent with the gen­er­al pop­u­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER